201 related articles for article (PubMed ID: 15556131)
1. Species comparison and pharmacological characterization of rat and human CB2 cannabinoid receptors.
Mukherjee S; Adams M; Whiteaker K; Daza A; Kage K; Cassar S; Meyer M; Yao BB
Eur J Pharmacol; 2004 Nov; 505(1-3):1-9. PubMed ID: 15556131
[TBL] [Abstract][Full Text] [Related]
2. Agonist-directed trafficking of response by endocannabinoids acting at CB2 receptors.
Shoemaker JL; Ruckle MB; Mayeux PR; Prather PL
J Pharmacol Exp Ther; 2005 Nov; 315(2):828-38. PubMed ID: 16081674
[TBL] [Abstract][Full Text] [Related]
3. Cloning and pharmacological characterization of the dog cannabinoid CB₂receptor.
Ndong C; O'Donnell D; Ahmad S; Groblewski T
Eur J Pharmacol; 2011 Nov; 669(1-3):24-31. PubMed ID: 21871882
[TBL] [Abstract][Full Text] [Related]
4. The endocannabinoid noladin ether acts as a full agonist at human CB2 cannabinoid receptors.
Shoemaker JL; Joseph BK; Ruckle MB; Mayeux PR; Prather PL
J Pharmacol Exp Ther; 2005 Aug; 314(2):868-75. PubMed ID: 15901805
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the role of nicotinic acetylcholine receptor subtypes and cannabinoid system in the discriminative stimulus effects of nicotine in rats.
Zaniewska M; McCreary AC; Przegaliński E; Filip M
Eur J Pharmacol; 2006 Jul; 540(1-3):96-106. PubMed ID: 16730696
[TBL] [Abstract][Full Text] [Related]
6. Species-specific in vitro pharmacological effects of the cannabinoid receptor 2 (CB2) selective ligand AM1241 and its resolved enantiomers.
Bingham B; Jones PG; Uveges AJ; Kotnis S; Lu P; Smith VA; Sun SC; Resnick L; Chlenov M; He Y; Strassle BW; Cummons TA; Piesla MJ; Harrison JE; Whiteside GT; Kennedy JD
Br J Pharmacol; 2007 Aug; 151(7):1061-70. PubMed ID: 17549048
[TBL] [Abstract][Full Text] [Related]
7. Anandamide-mediated CB1/CB2 cannabinoid receptor--independent nitric oxide production in rabbit aortic endothelial cells.
McCollum L; Howlett AC; Mukhopadhyay S
J Pharmacol Exp Ther; 2007 Jun; 321(3):930-7. PubMed ID: 17379772
[TBL] [Abstract][Full Text] [Related]
8. Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630.
Ross RA; Brockie HC; Stevenson LA; Murphy VL; Templeton F; Makriyannis A; Pertwee RG
Br J Pharmacol; 1999 Feb; 126(3):665-72. PubMed ID: 10188977
[TBL] [Abstract][Full Text] [Related]
9. Cannabinoid CB1 and CB2 receptor ligand specificity and the development of CB2-selective agonists.
Ashton JC; Wright JL; McPartland JM; Tyndall JD
Curr Med Chem; 2008; 15(14):1428-43. PubMed ID: 18537620
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy.
Valenzano KJ; Tafesse L; Lee G; Harrison JE; Boulet JM; Gottshall SL; Mark L; Pearson MS; Miller W; Shan S; Rabadi L; Rotshteyn Y; Chaffer SM; Turchin PI; Elsemore DA; Toth M; Koetzner L; Whiteside GT
Neuropharmacology; 2005 Apr; 48(5):658-72. PubMed ID: 15814101
[TBL] [Abstract][Full Text] [Related]
11. Functional Selectivity of CB2 Cannabinoid Receptor Ligands at a Canonical and Noncanonical Pathway.
Dhopeshwarkar A; Mackie K
J Pharmacol Exp Ther; 2016 Aug; 358(2):342-51. PubMed ID: 27194477
[TBL] [Abstract][Full Text] [Related]
12. Two Janus Cannabinoids That Are Both CB2 Agonists and CB1 Antagonists.
Dhopeshwarkar A; Murataeva N; Makriyannis A; Straiker A; Mackie K
J Pharmacol Exp Ther; 2017 Feb; 360(2):300-311. PubMed ID: 27927913
[TBL] [Abstract][Full Text] [Related]
13. Cannabinoid receptor agonists modulate calcium channels in rat retinal Müller cells.
Yang W; Li Q; Wang SY; Gao F; Qian WJ; Li F; Ji M; Sun XH; Miao Y; Wang Z
Neuroscience; 2016 Jan; 313():213-24. PubMed ID: 26621126
[TBL] [Abstract][Full Text] [Related]
14. Highly selective CB(1) cannabinoid receptor ligands and novel CB(1)/VR(1) vanilloid receptor "hybrid" ligands.
Di Marzo V; Bisogno T; De Petrocellis L; Brandi I; Jefferson RG; Winckler RL; Davis JB; Dasse O; Mahadevan A; Razdan RK; Martin BR
Biochem Biophys Res Commun; 2001 Feb; 281(2):444-51. PubMed ID: 11181068
[TBL] [Abstract][Full Text] [Related]
15. Sphingosine and its analog, the immunosuppressant 2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol, interact with the CB1 cannabinoid receptor.
Paugh SW; Cassidy MP; He H; Milstien S; Sim-Selley LJ; Spiegel S; Selley DE
Mol Pharmacol; 2006 Jul; 70(1):41-50. PubMed ID: 16571654
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the cannabinoid CB2 receptor-selective antagonist, SR144528: further evidence for cannabinoid CB2 receptor absence in the rat central nervous system.
Griffin G; Wray EJ; Tao Q; McAllister SD; Rorrer WK; Aung MM; Martin BR; Abood ME
Eur J Pharmacol; 1999 Jul; 377(1):117-25. PubMed ID: 10448934
[TBL] [Abstract][Full Text] [Related]
17. The third transmembrane helix of the cannabinoid receptor plays a role in the selectivity of aminoalkylindoles for CB2, peripheral cannabinoid receptor.
Chin CN; Murphy JW; Huffman JW; Kendall DA
J Pharmacol Exp Ther; 1999 Nov; 291(2):837-44. PubMed ID: 10525107
[TBL] [Abstract][Full Text] [Related]
18. A role for cannabinoid receptors, but not endogenous opioids, in the antinociceptive activity of the CB2-selective agonist, GW405833.
Whiteside GT; Gottshall SL; Boulet JM; Chaffer SM; Harrison JE; Pearson MS; Turchin PI; Mark L; Garrison AE; Valenzano KJ
Eur J Pharmacol; 2005 Dec; 528(1-3):65-72. PubMed ID: 16316650
[TBL] [Abstract][Full Text] [Related]
19. Functional consequences of nonsynonymous single nucleotide polymorphisms in the CB2 cannabinoid receptor.
Carrasquer A; Nebane NM; Williams WM; Song ZH
Pharmacogenet Genomics; 2010 Mar; 20(3):157-66. PubMed ID: 20124950
[TBL] [Abstract][Full Text] [Related]
20. Identification of raloxifene as a novel CB2 inverse agonist.
Kumar P; Song ZH
Biochem Biophys Res Commun; 2013 May; 435(1):76-81. PubMed ID: 23611779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
